Search
EHA statement on coronavirus (COVID-19)
The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).
Read moreEU commissioner Tonio Borg: 'we will continue to improve the life of people suffering from Thalassaemia'
Today, May 8, is International Thalassemia Day. Today, we seek to enhance the awareness and knowledge of thalassemia and other hemoglobin disorders.
SWG Educational Activities
Recruitment trialsRecruitment is underway for the following trials:
Trial on precision hematology: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2); ClinicalTrials.
Thrombocytopenias and Platelet Function Disorders
The SWG was established at the 2003 EHA Congress, which was held in Lyon, France. The group's original focus was thrombocytopenias, but it subsequently expanded its field of interest with the inclusion of platelet function disorders.
Read moreShining a Light on Blood Cancer
EHA Launches Digital Campaign
In September 2021, the European Hematology Association (EHA) will honor Blood Cancer Awareness Month with an extensive digital campaign.
Young researchers to benefit from EHA training and mentoring
Participation in EHA-CRTH will allow these researchers to fine-tune the skills and knowledge required to successfully design, run and complete clinical trials.
Read moreEHA Kick-off Grants
The call for applications is closed. The EHA Kick-off Grant is a one-year grant intended to support basic and translational early career researchers in hematology.
Read moreLighting the Flame program phases
A full guide to what our Lighting the Flame program involves, including dates of upcoming online workshops and in-person retreats.
Read morePROFILE Bootcamp in Entrepreneurial Innovation in Orphan Diseases, October 23-25, 2017, Leuven, Belgium.
Breaking innovations in rare diseases are at the centre of this PROFILE Bootcamp, which brings together junior & senior researchers, clinicians, pharmaceutical industry and policymakers.
Read more